Experienced in Thrombocytopenia

Dr. George N. Somlo

Hematology Oncology
1601 Island View Dr, 
Seal Beach, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Thrombocytopenia
1601 Island View Dr, 
Seal Beach, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

George Somlo is a Hematologist Oncology provider in Seal Beach, California. Dr. Somlo is rated as an Experienced provider by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Triple-Negative Breast Cancer, Multiple Myeloma, and Bone Marrow Transplant.

His clinical research consists of co-authoring 121 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Thrombocytopenia.

Specialties
Hematology Oncology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

1601 Island View Dr, Seal Beach, CA 90740
Other Locations
1500 E Duarte Rd, Duarte, CA 91010

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX)
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX)
Enrollment Status: Recruiting
Publish Date: August 20, 2025
Intervention Type: Diagnostic test
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors
A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: October 02, 2025
Intervention Type: Procedure, Other, Drug, Biological
Study Drugs: Entinostat, Ipilimumab, Nivolumab
Study Phase: Phase 1
Randomized Phase II Study of Docetaxel, Adriamycin, and Cytoxan (TAC) Versus Adriamycin/Cytoxan, Followed by Abraxane/Carboplatin (ACAC) +/- Trastuzumab as Neoadjuvant Therapy for Patients With Stage II-III Breast Cancer
Randomized Phase II Study of Docetaxel, Adriamycin, and Cytoxan (TAC) Versus Adriamycin/Cytoxan, Followed by Abraxane/Carboplatin (ACAC) +/- Trastuzumab as Neoadjuvant Therapy for Patients With Stage II-III Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Drug, Biological
Study Drugs: Trastuzumab, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 2
Phase II Prospective Open Label Study of Pertuzumab, Trastuzumab, and Nab-Paclitaxel in Patients With HER-2 Positive Advanced Breast Cancer
Phase II Prospective Open Label Study of Pertuzumab, Trastuzumab, and Nab-Paclitaxel in Patients With HER-2 Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Pertuzumab, Trastuzumab, Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Study Phase: Phase 2
Phase II Trial of Neoadjuvant Chemotherapy With Carboplatin and NAB-Paclitaxel in Patients With Locally Advanced and Inflammatory Triple Negative Breast Cancer
Phase II Trial of Neoadjuvant Chemotherapy With Carboplatin and NAB-Paclitaxel in Patients With Locally Advanced and Inflammatory Triple Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 03, 2025
Intervention Type: Drug, Other
Study Drugs: carboplatin, nab-paclitaxel
Study Phase: Phase 2
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Alpelisib
Study Phase: Phase 3
MK-3475 (Pembrolizumab) in Combination With an Anthracycline or Anti-estrogen Therapy in Patients With Triple Negative and Hormone Receptor Positive (HR+ HER2-) Metastatic Breast Cancer
MK-3475 (Pembrolizumab) in Combination With an Anthracycline or Anti-estrogen Therapy in Patients With Triple Negative and Hormone Receptor Positive (HR+ HER2-) Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: March 19, 2024
Intervention Type: Drug, Other, Biological
Study Drugs: Anastrozole, Doxorubicin Hydrochloride, Exemestane, Letrozole, Pembrolizumab
Study Phase: Phase 2
Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer
Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer
Enrollment Status: Completed
Publish Date: July 05, 2023
MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced & Inflammatory Breast Cancer
MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced & Inflammatory Breast Cancer
Enrollment Status: Completed
Publish Date: June 04, 2019
Phase I-II Single Cycle Melphalan/Total Marrow Irradiation (TMI) and Autologous Stem Cell Transplantation (ASCT) Followed by Maintenance in Patients With High-Risk Myeloma and/or Poor Response to Induction Therapy Within 12 Months of Diagnosis
Phase I-II Single Cycle Melphalan/Total Marrow Irradiation (TMI) and Autologous Stem Cell Transplantation (ASCT) Followed by Maintenance in Patients With High-Risk Myeloma and/or Poor Response to Induction Therapy Within 12 Months of Diagnosis
Enrollment Status: Withdrawn
Publish Date: December 13, 2017
Intervention Type: Drug, Procedure, Radiation, Other, Biological
Study Phase: Phase 1/Phase 2
View 10 Less Clinical Trials

121 Total Publications

Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer.
Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer.
Journal: medRxiv : the preprint server for health sciences
Published: September 05, 2025
Similar Doctors
Elite in Thrombocytopenia
Dr. Howard A. Liebman
Hematology Oncology | Hematology
Elite in Thrombocytopenia
Dr. Howard A. Liebman
Hematology Oncology | Hematology

USC Care Medical Group Inc

1500 San Pablo St, 
Los Angeles, CA 
 (22.5 miles away)
323-442-8444
Languages Spoken:
English
See accepted insurances

Howard Liebman is a Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Dr. Liebman is rated as an Elite provider by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Adult Immune Thrombocytopenia, Immune Thrombocytopenic Purpura (ITP), Thrombocytopenia, Purpura, and Splenectomy.

Distinguished in Thrombocytopenia
Dr. Sang H. Ahn
Hematology Oncology | Oncology | Hematology
Distinguished in Thrombocytopenia
Dr. Sang H. Ahn
Hematology Oncology | Oncology | Hematology

USC Care Medical Group Inc

5832 Beach Blvd, Unit 201, 
Buena Park, CA 
 (10.5 miles away)
714-522-0908
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sang Ahn is a Hematologist Oncology specialist and an Oncologist in Buena Park, California. Dr. Ahn is rated as an Elite provider by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Liver Cancer, Stomach Cancer, Breast Cancer, Thrombectomy, and Hepatectomy.

Distinguished in Thrombocytopenia
Dr. Roman L. Kleynberg
Hematology Oncology | Hematology | Oncology
Distinguished in Thrombocytopenia
Dr. Roman L. Kleynberg
Hematology Oncology | Hematology | Oncology

Advanced Hematology Oncology Medical Group Inc

6221 Wilshire Blvd, Suite 504, 
Los Angeles, CA 
 (26.7 miles away)
323-965-9995
Languages Spoken:
English
See accepted insurances

Roman Kleynberg is a Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Dr. Kleynberg is rated as a Distinguished provider by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Leukocytosis, Thrombocytopenia, Blood Clots, Gastrostomy, and Colonoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Somlo's expertise for a condition
ConditionClose
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile